US expansion focus Cyprotex is investing in a major US ADME facility expansion in Watertown and has unified branding under Cyprotex, signaling a push to capture more North American ADME-Tox demand and standardize service delivery for U.S. clients.

ADME-Tox leadership Recent and ongoing investments in high throughput ADME capabilities, plus expansion of the US site, indicate strong capability in in vitro ADME-Tox services that can be leveraged to upsell larger project scopes to small molecules and biotech clients.

Brand consolidation The name change from Apredica to Cyprotex and the movement of information to cyprotex.com present an opportunity to re-engage and migrate legacy Apredica customers to the Cyprotex platform with updated offerings and seamless contract continuity.

Global service portfolio With cross-site alignment of services between the UK and US locations and new online ordering channels, there is a chance to position Cyprotex as a single global ADME-Tox partner for clients seeking consistent standards and faster turnarounds.

Tech-enabled outreach The tech stack including SAP, Salesforce, and SAP HANA, along with a new e-store initiative, provides a foundation for targeted account-based marketing and streamlined sales workflows to convert inquiries into confirmed engagements.